Zimmer Biomet Reports Third Quarter 2017 Financial Results

|PR Newswire|About: ZBH

- Diluted EPS for the third quarter were $0.48, a decrease of 38.5% from the prior year period

- Adjusted diluted EPS for the third quarter were $1.72, a decrease of 3.9% from the prior year period

- The Company updates 2017 sales and earnings guidance

PR Newswire

WARSAW, Ind., Nov. 1, 2017 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (ZBH) (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2017.  The Company reported third quarter net sales of $1.818 billion, a decrease of 0.8% from the prior year period, and a decrease of 1.2% on a constant currency basis.  Excluding approximately 30 basis points of contribution from the LDR Holding Corporation (LDRH) acquisition, third quarter 2017 revenues decreased 1.1% from the third quarter of 2016, or 1.5% on a constant currency basis.

https://mma.prnewswire.com/media/594125/ZIMMER_BIOMET_LOGO.jpg

Diluted earnings per share for the quarter were $0.48, a decrease of 38.5% from the prior year period.  Adjusted diluted earnings per share for the quarter were $1.72, a decrease of 3.9% from the prior year period.

"Our top line results remained challenged during the third quarter, due to the pace of supply recovery of certain key brands, as well as softened domestic market conditions and slower than anticipated sales recapture, particularly in the United States," said Daniel P. Florin, Interim Chief Executive Officer, Senior Vice President and Chief Financial Officer of Zimmer Biomet.  "While we are not satisfied with our overall performance during the quarter, we remain confident in the Company's dedicated sales forces, the breadth of our portfolio and our strategic innovation pipeline.  Looking forward, our global teams will continue to make progress towards increasing supply availability and enabling commercial execution, which we expect will translate into accelerated sales growth."

Net earnings for the third quarter were $98.8 million, a decrease of 37.8% from the prior year period, and $349.9 million on an adjusted basis, a decrease of 3.4% from the prior year period.  Operating cash flow for the third quarter was $455.1 million.

In the quarter, the Company paid $48.5 million in dividends and declared a third quarter dividend of $0.24 per share.  The Company has repaid approximately $950 million of debt year-to-date in 2017.

Guidance

The Company is updating its full-year 2017 constant currency revenue and adjusted earnings per share guidance.  For the full year, the Company now expects revenue in the range of $7.76 billion to $7.80 billion, representing growth of 1.0% to 1.5% compared to the prior year and constant currency revenue growth of 0.9% to 1.4% compared to the prior year, inclusive of approximately 120 basis points of contribution from the LDR transaction.  Previously, the Company had expected full-year, constant currency revenue growth between 1.8% and 2.7%, inclusive of approximately 120 basis points of contribution from the LDR transaction.  Additionally, the Company now expects its full-year 2017 diluted earnings per share to be in a range of $3.80 to $3.93, and in a range of $8.01 to $8.07 on an adjusted basis.  Previously, the Company had expected full-year 2017 diluted earnings per share to be in a range of $4.15 to $4.35, and in a range of $8.20 to $8.30 on an adjusted basis.

For the fourth quarter of 2017, the Company expects revenue in the range of $2.01 billion to $2.05 billion, representing growth of 0% to positive 2.0% compared to the prior year period and constant currency revenue growth of negative 1.8% to positive 0.2% compared to the prior year period.  Additionally, the Company expects its diluted earnings per share for the fourth quarter to be in a range of $0.94 to $1.08, and in a range of $2.08 to $2.14 on an adjusted basis.

Conference Call and Earnings Release Information

The Company will conduct its third quarter 2017 investor conference call today, November 1, 2017 at 8:00 a.m. Eastern Time.  The audio webcast and earnings release information, including the Company's third quarter investor presentation, can be accessed via Zimmer Biomet's Investor Relations website at http://investor.zimmerbiomet.com.  The audio webcast will be archived for replay following the conference call.

Individuals in the U.S. and Canada who wish to dial into the conference call may do so by dialing (888) 312-9837 and entering conference ID 7278985.  For a complete listing of international toll-free and local numbers, please visit http://investor.zimmerbiomet.com.  A digital recording will be available 24 hours after the completion of the conference call, from November 2, 2017 to December 1, 2017.  To access the recording, U.S. callers should dial (888) 203-1112 and international callers should dial +1 (719) 457-0820, and enter the Access Code ID 7278985.

Sales Tables

The following sales tables provide results by geography and product category, as well as the percentage change compared to the prior year quarter and nine months, on both a reported and a constant currency basis. 

 

NET SALES - THREE MONTHS ENDED SEPTEMBER 30, 2017

(in millions, unaudited)
























Constant




Net








Currency




Sales



% Change




% Change



Geographic Results














Americas

$

1,142




(2.9)


%



(3.0)


%

EMEA


381




3.3





(0.4)



Asia Pacific


295




2.4





5.2



Total

$

1,818




(0.8)


%



(1.2)


%

Product Categories














Knees














Americas

$

383




(3.8)


%



(3.9)


%

EMEA


135




3.7





0.6



Asia Pacific


106




2.3





3.9



Total


624




(1.2)





(1.7)



Hips














Americas


228




(4.5)





(4.7)



EMEA


115




2.4





(1.5)



Asia Pacific


91




2.1





6.1



Total


434




(1.4)





(1.7)

















S.E.T (1)


407




1.2





1.1



Dental


93




(3.2)





(4.4)



Spine & CMF


185




0.7





0.3



Other


75




(4.8)





(5.3)



Total

$

1,818




(0.8)


%



(1.2)


%

 

(1)  Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma

 

NET SALES - NINE MONTHS ENDED SEPTEMBER 30, 2017

(in millions, unaudited)











Constant




Net







Currency




Sales



% Change



% Change



Geographic Results













Americas

$

3,586




1.5


%


1.4


%

EMEA


1,272




(1.0)




0.4



Asia Pacific


892




4.8




6.0



Total

$

5,750




1.4


%


1.8


%

Product Categories













Knees













Americas

$

1,217




(2.2)


%


(2.2)


%

EMEA


463




(2.2)




(0.1)



Asia Pacific


326




3.5




3.8



Total


2,006




(1.3)




(0.8)



Hips













Americas

$

720




(1.9)




(1.9)



EMEA


382




(1.5)




(0.6)



Asia Pacific


278




5.3




7.2



Total


1,380




(0.4)




0.2
















S.E.T (1)


1,255




3.3




3.7



Dental


311




(3.5)




(3.4)



Spine & CMF


565




20.1




20.1



Other


233




(4.9)




(4.5)



Total

$

5,750




1.4


%


1.8


%

 

(1)  Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma

 

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet

Website Information

We routinely post important information for investors on our website, www.zimmerbiomet.com, in the "Investor Relations" section.  We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD.  Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts.  The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.

Note on Non-GAAP Financial Measures

This press release includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP").  These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP.

Sales change information for the three- and nine-month periods ended September 30, 2017 is presented on a GAAP (reported) basis and on a constant currency basis, as well as on a basis that excludes the contribution from the Company's acquisition of LDR Holding Corporation in July 2016.  Projected revenue change information is also presented on a GAAP basis and on a constant currency basis.  Constant currency rates exclude the effects of foreign currency exchange rates.  They are calculated by translating current and prior-period sales at the same predetermined exchange rate.  The translated results are then used to determine year-over-year percentage increases or decreases.  Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are included in this press release.

Net earnings, diluted earnings per share and projected diluted earnings per share are presented on a GAAP (reported) basis and on an adjusted basis.  Adjusted earnings and adjusted diluted earnings per share exclude the effects of inventory step-up; certain inventory and manufacturing-related charges connected to discontinuing certain product lines, quality enhancement and remediation efforts; special items; intangible asset amortization; any related effects on our income tax provision associated with these items; and other certain tax adjustments.  Special items include expenses resulting directly from our business combinations and/or global restructuring, quality and operational excellence initiatives, including employee termination benefits, certain contract terminations, consulting and professional fees, dedicated project personnel, asset impairment or loss on disposal charges, certain litigation matters, costs of complying with our deferred prosecution agreement and other items.  Other certain tax adjustments include a tax restructuring that lowered the tax rate on deferred tax liabilities recorded on intangible assets recognized in acquisition-related accounting, net favorable resolutions of various tax matters, and charges from internal restructuring transactions that provide the Company access to cash in a tax efficient manner.

Management uses these non-GAAP financial measures internally to evaluate the performance of the business and believes they are useful measures that provide meaningful supplemental information to investors to consider when evaluating the performance of the Company.  Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported operating results, to perform trend analysis, to better identify operating trends that may otherwise be masked or distorted by these types of items and to provide additional transparency of certain items.  In addition, certain of these non-GAAP financial measures are used as performance metrics in the Company's incentive compensation programs.

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding sales and earnings guidance and any statements about our expectations, plans, strategies or prospects.  We generally use the words "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," "sees," "seeks," "should," "could," "intends" and similar expressions to identify forward-looking statements.  Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially.  These risks, uncertainties and changes in circumstances include, but are not limited to: our chief executive officer transition, including disruptions and uncertainties related thereto, our ability to appoint a permanent successor with the desired level of experience and expertise in a timely manner, the potential impact on our business and future strategic direction resulting from our transition to a new chief executive officer, and our ability to retain other key members of senior management; the possibility that the anticipated synergies and other benefits from mergers and acquisitions will not be realized, or will not be realized within the expected time periods; the risks and uncertainties related to our ability to successfully integrate the operations, products, employees and distributors of acquired companies; the effect of the potential disruption of management's attention from ongoing business operations due to integration matters related to mergers and acquisitions; the effect of mergers and acquisitions on our relationships with customers, vendors and lenders and on our operating results and businesses generally; compliance with the Deferred Prosecution Agreement entered into in January 2017; the success of our quality and operational excellence initiatives, including ongoing quality enhancement and remediation efforts at the legacy Biomet Warsaw facility; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration (FDA) and foreign government regulators, such as more stringent requirements for regulatory clearance of products; the ability to remediate matters identified in any inspectional observations or warning letters issued by the FDA, while continuing to satisfy the demand for our products; the outcome of government investigations; competition; pricing pressures; changes in customer demand for our products and services caused by demographic changes or other factors; the impact of healthcare reform measures; reductions in reimbursement levels by third-party payors and cost containment efforts of healthcare purchasing organizations; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products; control of costs and expenses; the ability to obtain and maintain adequate intellectual property protection; the ability to form and implement alliances; changes in tax obligations arising from tax reform measures, including European Union rules on state aid, or examinations by tax authorities; product liability and intellectual property litigation losses; the ability to retain the independent agents and distributors who market our products; dependence on a limited number of suppliers for key raw materials and outsourced activities; changes in general industry and market conditions, including domestic and international growth rates; changes in general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; and the impact of the ongoing financial and political uncertainty on countries in the Euro zone on the ability to collect accounts receivable in affected countries.  For a further list and description of such risks and uncertainties, see our reports filed with the U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2016 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.  Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.zimmerbiomet.com or on request from us.  Forward-looking statements speak only as of the date they are made, and we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  Readers of this release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate.  This cautionary statement is applicable to all forward-looking statements contained in this release.

 

ZIMMER BIOMET HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF EARNINGS

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017 and 2016

(in millions, except per share amounts, unaudited)








2017



2016


Net Sales

$

1,818.1



$

1,832.8


Cost of products sold, excluding intangible asset amortization


500.9




479.3


Intangible asset amortization


152.7




164.3


Research and development


91.2




95.6


Selling, general and administrative


694.5




727.7


Special items


165.4




170.4


Operating expenses


1,604.7




1,637.3


Operating Profit


213.4




195.5


Other expense, net


(4.5)




(1.1)


Interest income


0.6




0.6


Interest expense


(82.3)




(91.5)


Earnings before income taxes


127.2




103.5


Provision (benefit) for income taxes


28.4




(54.4)


Net Earnings


98.8




157.9


Less: Net Loss attributable to noncontrolling interest


-




(0.9)


Net Earnings of Zimmer Biomet Holdings, Inc.

$

98.8



$

158.8


Earnings Per Common Share








Basic

$

0.49



$

0.79


Diluted

$

0.48



$

0.78


Weighted Average Common Shares Outstanding








Basic


202.3




200.1


Diluted


204.0




202.9


Cash Dividends Declared Per Common Share

$

0.24



$

0.24


 

ZIMMER BIOMET HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF EARNINGS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017 and 2016

(in millions, except per share amounts, unaudited)



2017



2016


Net Sales

$

5,749.8



$

5,670.8


Cost of products sold, excluding intangible asset amortization


1,541.5




1,760.0


Intangible asset amortization


452.4




424.7


Research and development


272.4




269.9


Selling, general and administrative


2,203.3




2,176.6


Special items


434.1




397.0


Operating expenses


4,903.7




5,028.2


Operating Profit


846.1




642.6


Other expense, net


(11.2)




(8.7)


Interest income


1.4




2.7


Interest expense


(247.5)




(267.8)


Earnings before income taxes


588.8




368.8


Provision for income taxes


6.6




133.9


Net Earnings


582.2




234.9


Less: Net Loss attributable to noncontrolling interest


(0.2)




(1.4)


Net Earnings of Zimmer Biomet Holdings, Inc.

$

582.4



$

236.3


Earnings Per Common Share








Basic

$

2.89



$

1.18


Diluted

$

2.86



$

1.17


Weighted Average Common Shares Outstanding








Basic


201.7




199.9


Diluted


203.6




202.3


Cash Dividends Declared Per Common Share

$

0.72



$

0.72


 

ZIMMER BIOMET HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions, unaudited)




September 30,



December 31,




2017



2016


Assets









Cash and cash equivalents


$

480.8



$

634.1


Receivables, net



1,318.5




1,604.4


Inventories



2,084.2




1,959.4


Other current assets



549.8




465.7


Total current assets



4,433.3




4,663.6


Property, plant and equipment, net



2,048.6




2,037.9


Goodwill



10,904.9




10,643.9


Intangible assets, net



8,464.9




8,785.4


Other assets



565.8




553.6


Total Assets


$

26,417.5



$

26,684.4


Liabilities and Stockholders' Equity









Current liabilities


$

1,785.2



$

1,805.9


Current portion of long-term debt



1,225.0




575.6


Other long-term liabilities



3,757.4




3,967.2


Long-term debt



9,199.7




10,665.8


Stockholders' equity



10,450.2




9,669.9


Total Liabilities and Stockholders' Equity


$

26,417.5



$

26,684.4


 

ZIMMER BIOMET HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017 and 2016

(in millions, unaudited)




2017



2016


Cash flows provided by (used in) operating activities









Net earnings


$

582.2



$

234.9


Depreciation and amortization



798.2




787.3


Share-based compensation



40.1




45.9


Goodwill and intangible asset impairment



59.5




28.0


Inventory step-up



32.2




300.9


Changes in operating assets and liabilities, net of acquired assets and liabilities









Income taxes



(245.4)




(125.4)


Receivables



349.7




(80.3)


Inventories



(123.2)




44.2


Accounts payable and accrued expenses



(173.6)




(76.0)


Other assets and liabilities



(140.3)




(154.5)


Net cash provided by operating activities



1,179.4




1,005.0


Cash flows provided by (used in) investing activities









Additions to instruments



(255.7)




(251.3)


Additions to other property, plant and equipment



(109.8)




(130.1)


Purchases of investments



-




(1.4)


Sales of investments



-




273.3


LDR acquisition, net of acquired cash



-




(1,021.1)


Business combination investments, net of acquired cash



(4.0)




(421.9)


Other investing activities



(13.1)




7.8


Net cash used in investing activities



(382.6)




(1,544.7)


Cash flows provided by (used in) financing activities









Proceeds from multicurrency revolving facility



400.0




-


Payments on multicurrency revolving facility



(400.0)




-


Redemption of senior notes



(500.0)




-


Proceeds from term loan



192.7




750.0


Payments on term loan



(640.0)




(700.0)


Net payments on other debt



(0.9)




(33.1)


Dividends paid to stockholders



(145.0)




(140.3)


Proceeds from employee stock compensation plans



132.6




113.5


Business combination contingent consideration payments



(9.1)




-


Restricted stock witholdings



(7.6)




(5.3)


Debt issuance costs



(0.3)




(3.4)


Repurchase of common stock



-




(415.5)


Net cash used in financing activities



(977.6)




(434.1)


Effect of exchange rates on cash and cash equivalents



27.5




(10.2)


Decrease in cash and cash equivalents



(153.3)




(984.0)


Cash and cash equivalents, beginning of period



634.1




1,459.3


Cash and cash equivalents, end of period


$

480.8



$

475.3


 

ZIMMER BIOMET HOLDINGS, INC.

NET SALES BY GEOGRAPHY

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 and 2016

(in millions, unaudited)




Three Months Ended September 30,




Nine Months Ended September 30,





2017



2016



% Inc /

(Dec)




2017



2016



% Inc /

(Dec)



Americas


$

1,142.0



$

1,175.9




(2.9)


%


$

3,585.6



$

3,534.1




1.5


%

EMEA



381.1




368.8




3.3





1,272.5




1,286.0




(1.0)



Asia Pacific



295.0




288.1




2.4





891.7




850.7




4.8



Total


$

1,818.1



$

1,832.8




(0.8)


%


$

5,749.8



$

5,670.8




1.4


%

 

ZIMMER BIOMET HOLDINGS, INC.

NET SALES BY PRODUCT CATEGORY

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 and 2016

(in millions, unaudited)




Three Months Ended September 30,




Nine Months Ended September 30,





2017



2016



% Inc /

(Dec)




2017



2016



% Inc /

(Dec)



Knees


$

623.7



$

631.5




(1.2)


%


$

2,005.9



$

2,031.7




(1.3)


%

Hips



434.5




440.6




(1.4)





1,380.0




1,385.7




(0.4)



S.E.T



406.6




401.8




1.2





1,254.5




1,215.0




3.3



Dental



92.9




95.9




(3.2)





311.1




322.5




(3.5)



Spine & CMF



184.9




183.7




0.7





565.2




470.7




20.1



Other



75.5




79.3




(4.8)





233.1




245.2




(4.9)



Total


$

1,818.1



$

1,832.8




(0.8)


%


$

5,749.8



$

5,670.8




1.4


%

 

ZIMMER BIOMET HOLDINGS, INC.

RECONCILIATION OF REPORTED NET SALES % CHANGE TO

CONSTANT CURRENCY % CHANGE AND

% CHANGE EXCLUDING LDR HOLDING CORPORATION

(unaudited)



For the Three Months Ended




September 30, 2017









Foreign




Constant









Exchange




Currency




% Change




Impact




% Change



Geographic Results















Americas


(2.9)


%



0.1


%



(3.0)


%

EMEA


3.3





3.7





(0.4)



Asia Pacific


2.4





(2.8)





5.2



Total


(0.8)


%



0.4


%



(1.2)


%

Product Categories















Knees















Americas


(3.8)


%



0.1


%



(3.9)


%

EMEA


3.7





3.1





0.6



Asia Pacific


2.3





(1.6)





3.9



Total


(1.2)





0.5





(1.7)



Hips















Americas


(4.5)





0.2





(4.7)



EMEA


2.4





3.9





(1.5)



Asia Pacific


2.1





(4.0)





6.1



Total


(1.4)





0.3





(1.7)


















S.E.T


1.2





0.1





1.1



Dental


(3.2)





1.2





(4.4)



Spine & CMF


0.7





0.4





0.3



Other


(4.8)





0.5





(5.3)



Total


(0.8)


%



0.4


%



(1.2)


%

Impact of additional LDR Holding Corporation

    billing days in the 2017 period


(0.3)





-





(0.3)



% Change excluding LDR Holding Corporation


(1.1)


%



0.4


%



(1.5)


%

 

ZIMMER BIOMET HOLDINGS, INC.

RECONCILIATION OF REPORTED NET SALES % CHANGE TO

CONSTANT CURRENCY % CHANGE AND

% CHANGE EXCLUDING LDR HOLDING CORPORATION

(unaudited)



For the Nine Months Ended




September 30, 2017









Foreign




Constant









Exchange




Currency




% Change




Impact




% Change



Geographic Results















Americas


1.5


%



0.1


%



1.4


%

EMEA


(1.0)





(1.4)





0.4



Asia Pacific


4.8





(1.2)





6.0



Total


1.4


%



(0.4)


%



1.8


%
















Product Categories















Knees















Americas


(2.2)


%



-


%



(2.2)


%

EMEA


(2.2)





(2.1)





(0.1)



Asia Pacific


3.5





(0.3)





3.8



Total


(1.3)





(0.5)





(0.8)


















Hips















Americas


(1.9)





-





(1.9)



EMEA


(1.5)





(0.9)





(0.6)



Asia Pacific


5.3





(1.9)





7.2



Total


(0.4)





(0.6)





0.2


















S.E.T


3.3





(0.4)





3.7



Dental


(3.5)





(0.1)





(3.4)



Spine & CMF


20.1





-





20.1



Other


(4.9)





(0.4)





(4.5)



Total


1.4


%



(0.4)


%



1.8


%

Impact of additional LDR Holding Corporation

    billing days in the 2017 period


(1.6)





-





(1.6)



% Change excluding LDR Holding Corporation


(0.2)


%



(0.4)


%



0.2


%

 

ZIMMER BIOMET HOLDINGS, INC.

RECONCILIATION OF NET EARNINGS TO ADJUSTED NET EARNINGS

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017 and 2016

(in millions, unaudited)




Three Months




Ended September 30,




2017



2016


 Net Earnings of Zimmer Biomet Holdings, Inc.


$

98.8



$

158.8


 Inventory step-up and other inventory  and manufacturing-related charges



10.4




22.8


 Intangible asset amortization



152.7




164.3


 Special items









 Biomet merger-related



81.1




113.8


 Other special items



84.3




56.6


 Merger-related and other (income) expense in other expense, net



(0.5)




(2.6)


Taxes on above items (1)



(79.1)




(111.6)


Other certain tax adjustments (2)



2.2




(39.7)


 Adjusted Net Earnings


$

349.9



$

362.4


 

(1)   The tax effect for the U.S. jurisdiction is calculated based on an effective rate considering federal and state taxes, as well as permanent items. For jurisdictions outside the U.S., the tax effect is calculated based upon the statutory rates where the items were incurred.

(2)   In 2017, other certain tax adjustments relate to net unfavorable resolutions of various tax matters. The 2016 adjustment primarily relates to a favorable adjustment to certain deferred tax liabilities recognized as part of acquisition-related accounting.

 

ZIMMER BIOMET HOLDINGS, INC.

RECONCILIATION OF NET EARNINGS TO ADJUSTED NET EARNINGS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017 and 2016

(in millions, unaudited)




Nine Months




Ended September 30,




2017



2016


Net Earnings of Zimmer Biomet Holdings, Inc.


$

582.4



$

236.3


Inventory step-up and other inventory and manufacturing-related charges



58.5




357.7


Intangible asset amortization



452.4




424.7


Special items









Biomet (BMET) merger-related



206.3




313.5


Other special items



227.8




83.5


Merger-related and other (income) expense in other expense, net



0.5




(1.1)


Taxes on above items (1)



(264.4)




(297.0)


Biomet merger-related measurement period tax adjustments (2)



-




52.7


Other certain tax adjustments (3)



(55.6)




6.4


Adjusted Net Earnings


$

1,207.9



$

1,176.7


 

(1)   The tax effect for the U.S. jurisdiction is calculated based on an effective rate considering federal and state taxes, as well as permanent items. For jurisdictions outside the U.S., the tax effect is calculated based upon the statutory rates where the items were incurred.

(2)   The 2016 period includes negative effects from finalizing the tax accounts for the Biomet merger.  Under the applicable U.S. GAAP rules, these measurement period adjustments are recognized on a prospective basis in the period of change.

(3)   In 2017, other certain tax adjustments relate to a tax restructuring that lowered the tax rate on deferred tax liabilities recorded on intangible assets recognized in acquisition-related accounting, net favorable resolutions of various tax matters, and charges from internal restructuring transactions that provide the Company access to cash in a tax efficient manner.  The 2016 adjustment primarily relates to a favorable adjustment to certain deferred tax liabilities recognized as part of acquisition-related accounting offset by internal restructuring transactions that provide the Company access to cash in a tax efficient manner.

 

ZIMMER BIOMET HOLDINGS, INC.

RECONCILIATION OF DILUTED EPS TO ADJUSTED DILUTED EPS

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017 and 2016

(unaudited)



Three Months



Ended September 30,



2017



2016


Diluted EPS

$

0.48



$

0.78


Inventory step-up and other inventory and manufacturing-related charges


0.05




0.11


Intangible asset amortization


0.75




0.81


Special items








Biomet merger-related


0.40




0.56


Other special items


0.41




0.28


Merger-related expense in other expense, net


-




(0.01)


Taxes on above items (1)


(0.38)




(0.55)


Other certain tax adjustments (2)


0.01




(0.19)


Adjusted Diluted EPS

$

1.72



$

1.79


 

(1)   The tax effect for the U.S. jurisdiction is calculated based on an effective rate considering federal and state taxes, as well as permanent items.  For jurisdictions outside the U.S., the tax effect is calculated based upon the statutory rates where the items were incurred.

(2)   In 2017, other certain tax adjustments relate to net unfavorable resolutions of various tax matters. The 2016 adjustment primarily relates to a favorable adjustment to certain deferred tax liabilities recognized as part of acquisition-related accounting.

 

ZIMMER BIOMET HOLDINGS, INC.

RECONCILIATION OF DILUTED EPS TO ADJUSTED DILUTED EPS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017 and 2016

(unaudited)



Nine Months



Ended September 30,



2017



2016


Diluted EPS

$

2.86



$

1.17


Inventory step-up and other inventory and manufacturing-related charges


0.29




1.77


Intangible asset amortization


2.22




2.10


Special items








Biomet merger-related


1.01




1.55


Other special items


1.12




0.41


Merger-related and other expense in other expense, net


-




(0.01)


Taxes on above items (1)


(1.30)




(1.47)


Biomet merger-related measurement period tax adjustments (2)


-




0.26


Other certain tax adjustments (3)


(0.27)




0.04


Adjusted Diluted EPS

$

5.93



$

5.82


 

(1)   The tax effect for the U.S. jurisdiction is calculated based on an effective rate considering federal and state taxes, as well as permanent items. For jurisdictions outside the U.S., the tax effect is calculated based upon the statutory rates where the items were incurred.

(2)   The 2016 period includes negative effects from finalizing the tax accounts for the Biomet merger.  Under the applicable U.S. GAAP rules, these measurement period adjustments are recognized on a prospective basis in the period of change.

(3)   In 2017, other certain tax adjustments relate to a tax restructuring that lowered the tax rate on deferred tax liabilities recorded on intangible assets recognized in acquisition-related accounting, net favorable resolutions of various tax matters, and charges from internal restructuring transactions that provide the Company access to cash in a tax efficient manner.  The 2016 adjustment primarily relates to a favorable adjustment to certain deferred tax liabilities recognized as part of acquisition-related accounting offset by internal restructuring transactions that provide the Company access to cash in a tax efficient manner.

 

 ZIMMER BIOMET HOLDINGS, INC.

SUMMARY OF EXPENSES INCLUDED IN SPECIAL ITEMS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 and 2016

(in millions, unaudited)




Three Months



Nine Months




Ended September 30,



Ended September 30,




2017



2016



2017



2016


Biomet merger-related

















Consulting and professional fees


$

19.9



$

59.0



$

60.7



$

138.4


Employee termination benefits



5.4




7.1




12.0




14.3


Dedicated project personnel



10.2




21.9




33.1




64.8


Relocated facilities



1.8




9.5




6.1




17.5


Certain litigation matters



5.0




-




5.0




-


Contract terminations



-




3.5




-




28.8


Information technology integration



1.3




4.8




4.9




9.3


Goodwill and intangible asset impairment



32.7




-




59.5




28.0


Other



4.8




8.0




25.0




12.4


Total Biomet merger-related



81.1




113.8




206.3




313.5


Other

















Consulting and professional fees



56.3




14.6




158.4




30.3


Employee termination benefits



(0.6)




3.2




2.0




3.2


Dedicated project personnel



14.0




8.2




35.5




11.5


Impairment/loss on disposal of assets



-




-




-




1.1


LDR merger consideration compensation expense



-




24.1




-




24.1


Relocated facilities



0.6




-




3.1




0.2


Certain litigation matters



3.0




3.7




10.0




3.7


Contract terminations



-




0.1




-




1.1


Information technology integration



1.0




0.8




1.8




1.1


Certain R&D agreements



-




-




2.5




-


Contingent consideration adjustments



1.7




-




(1.5)




-


Other



8.3




1.9




16.0




7.2


Total Other



84.3




56.6




227.8




83.5


Special items


$

165.4



$

170.4



$

434.1



$

397.0


 

ZIMMER BIOMET HOLDINGS, INC.

RECONCILIATION OF 2017 PROJECTED REVENUE % CHANGE TO

2017 PROJECTED CONSTANT CURRENCY % CHANGE AND

CHANGE EXCLUDING LDR HOLDING CORPORATION

(unaudited)


Projected Three Months Ended December 31, 2017:

High




Low



Revenue % change


2.0


%



-


%

Foreign exchange impact


(1.8)





(1.8)



Constant currency % change


0.2


%



(1.8)


%











Projected Year Ended December 31, 2017:

High




Low



Revenue % change


1.5


%



1.0


%

Foreign exchange impact


(0.1)





(0.1)



Constant currency % change


1.4


%



0.9


%

Impact of LDR Holding Corporation


(1.2)





(1.2)



Constant currency % change excluding LDR Holding Corporation


0.2


%



(0.3)


%

 

ZIMMER BIOMET HOLDINGS, INC.

RECONCILIATION OF 2017 PROJECTED DILUTED EPS

AND PROJECTED ADJUSTED DILUTED EPS

(unaudited)


Projected Three Months Ended December 31, 2017:

High



Low


Diluted EPS

$

1.08



$

0.94


Inventory step-up and other inventory and manufacturing related charges, intangible asset amortization, special items and other expense


1.48




1.60


Taxes on above items(1) and other certain tax adjustments


(0.42)




(0.46)


Adjusted Diluted EPS

$

2.14



$

2.08










Projected Year Ended December 31, 2017:

High



Low


Diluted EPS

$

3.93



$

3.80


Inventory step-up and other inventory and manufacturing related charges, intangible asset amortization, special items and other expense


6.14




6.24


Taxes on above items(1) and other certain tax adjustments


(2.00)




(2.03)


Adjusted Diluted EPS

$

8.07



$

8.01


 

(1)   The tax effect for the U.S. jurisdiction is estimated based on an effective rate considering federal and state taxes, as well as permanent items.  For jurisdictions outside the U.S., the tax effect is estimated based upon the statutory rates where the items are projected to be incurred.

View original content with multimedia:http://www.prnewswire.com/news-releases/zimmer-biomet-reports-third-quarter-2017-financial-results-300546950.html

SOURCE Zimmer Biomet Holdings, Inc.